TNFα is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 3, 2011, Pages 1336-1344

  Huang, Hu ^a   Gandhi, Jarel K ^a   Zhong, Xiufeng ^a   Wei, Yanhong ^a   Gong, Junsong ^a   Duh, Elia J ^a   Vinores, Stanley A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD31 ANTIGEN; FLUORESCEIN ISOTHIOCYANATE; TUMOR NECROSIS FACTOR ALPHA; ACTIN; CASP3 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD RETINA BARRIER; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE DURATION; ENDOTHELIUM CELL; INFLAMMATION; LEUKOCYTE; LEUKOSTASIS; MALE; MOUSE; NEUROPROTECTION; NICK END LABELING; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; RETINA BLOOD VESSEL; RETINA NERVE CELL; ANIMAL; C57BL MOUSE; CAPILLARY PERMEABILITY; CELL SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL DIABETES MELLITUS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE SILENCING; GENOTYPE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACTINS; ANIMALS; ANTIGENS, CD31; APOPTOSIS; BLOOD-RETINAL BARRIER; CAPILLARY PERMEABILITY; CASPASE 3; CELL SURVIVAL; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE SILENCING; GENOTYPE; IN SITU NICK-END LABELING; LEUKOSTASIS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RETINAL NEURONS; RETINAL VESSELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79955943133     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-5768     Document Type: Article

References (66)

1. Cunha-Vaz JG. The blood-retinal barriers. Doc Ophthalmol. 1976; 41:287-327.
2. Cunha-Vaz JG. Blood-retinal barriers in health and disease. Trans Ophthalmol Soc U K. 1980;100:337-340.
3. Vinores SA, Kuchle M, Derevjanik NL, et al. Blood-retinal barrier breakdown in retinitis pigmentosa: light and electron microscopic immunolocalization. Histol Histopathol. 1995;10:913-923.
4. Vinores SA, Derevjanik NL, Ozaki H, et al. Cellular mechanisms of blood-retinal barrier dysfunction in macular edema. Doc Ophthalmol. 1999;97:217-228.
5. Barber AJ, Antonetti DA, Gardner TW. Altered expression of retinal occludin and glial fibrillary acidic protein in experimental diabetes. The Penn State Retina Research Group. Invest Ophthalmol Vis Sci. 2000;41:3561-3568.
6. Saishin Y, Takahashi K, Melia M, et al. Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier. J Cell Physiol. 2003;195:210-219.
7. Vinores SA, Derevjanik NL, Vinores MA, et al. Sensitivity of different vascular beds in the eye to neovascularization and blood-retinal barrier breakdown in VEGF transgenic mice. Adv Exp Med Biol. 2000;476:129-138.
8. Vinores SA, Xiao WH, Aslam S, et al. Implication of the hypoxia response element of the Vegf promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J Cell Physiol. 2006;206:749-758.
9. Miyamoto K, Khosrof S, Bursell SE, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A. 1999;96:10836-10841.
10. Joussen AM, Murata T, Tsujikawa A, et al. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol. 2001;158:147-152.
11. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol. 2008;30: 65-84.
12. Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18: 1450-1452.
13. Chibber R, Ben-Mahmud BM, Chibber S, Kohner EM. Leukocytes in diabetic retinopathy. Curr Diabetes Rev. 2007;3:3-14.
14. Patel N. Targeting leukostasis for the treatment of early diabetic retinopathy. Cardiovasc Hematol Disord Drug Targets. 2009;9: 222-229.
15. Lu M, Perez VL, Ma N, et al. VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci. 1999;40:1808-1812.
16. Joussen AM, Poulaki V, Qin W, et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol. 2002;160: 501-509.
17. Clauss M, Sunderkotter C, Sveinbjornsson B, et al. A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability. Blood. 2001;97:1321-1329.
18. Vinores SA, Xiao WH, Shen J, Campochiaro PA. TNF-alpha is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage. J Neuroimmunol. 2007;182:73-79.
19. Joussen AM, Doehmen S, Le ML, et al. TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol Vis. 2009;15:1418-1428.
20. Leal EC, Manivannan A, Hosoya K, et al. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2007;48:5257-5265.
21. Kim JH, Yu YS, Cho CS, Kim KW. Blockade of angiotensin II attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy. J Cereb Blood Flow Metab. 2009;29:621-628.
22. Wilkinson-Berka JL. Diabetes and retinal vascular disorders: role of the renin-angiotensin system. Expert Rev Mol Med. 2004;6:1-18.
23. Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 2002b;16:438-440.
24. Zhang SX, Wang JJ, Gao G, et al. Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J. 2006; 20:323-325.
25. Franks WA, Limb GA, Stanford MR, et al. Cytokines in human intraocular inflammation. Curr Eye Res. 1992;11(suppl):187-191.
26. Limb GA, Chignell AH, Green W, et al. Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol. 1996;80:168-173.
27. Limb GA, Webster L, Soomro H, et al. Platelet expression of tumour necrosis factor-alpha (TNF-alpha), TNF receptors and intercellular adhesion molecule-1 (ICAM-1) in patients with proliferative diabetic retinopathy. Clin Exp Immunol. 1999;118:213-218.
28. Spranger J, Meyer-Schwickerath R, Klein M, et al. TNF-alpha level in the vitreous body: increase in neovascular eye diseases andproliferative diabetic retinopathy (in German). Med Klin (Munich) 1995;90:134-137.
29. Lechleitner M, Koch T, Herold M, et al. Tumour necrosis factoralpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors. J Intern Med. 2000;248:67-76.
30. Yuuki T, Kanda T, Kimura Y, et al. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complications. 2001;15:257-259.
31. Barber AJ, Antonetti DA, Kern TS, et al. The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci. 2005;46:2210-2218.
32. Phelan SA, Ito M, Loeken MR. Neural tube defects in embryos of diabetic mice: role of the Pax-3 gene and apoptosis. Diabetes. 1997;46:1189-1197.
33. Derevjanik NL, Vinores SA, Xiao WH, et al. Quantitative assessment of the integrity of the blood-retinal barrier in mice. Invest Ophthalmol Vis Sci. 2002;43:2462-2467.
34. Tobe T, Okamoto N, Vinores MA, et al. Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors. Invest Ophthalmol Vis Sci. 1998;39: 180-188.
35. Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York: Springer-Verlag, Inc.; 2000.
36. Kern TS, Du Y, Miller CM, et al. Overexpression of Bcl-2 in vascular endothelium inhibits the microvascular lesions of diabetic retinopathy. Am J Pathol. 2010;176:2550-2558.
37. Kociok N, Radetzky S, Krohne TU, et al. Pathological but not physiological retinal neovascularization is altered in TNF-Rp55-receptor-deficient mice. Invest Ophthalmol Vis Sci. 2006;47: 5057-5065.
38. Ehrlich R, Harris A, Ciulla TA, et al. Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process. Acta Ophthalmol. 2010;88:279-291.
39. Duh E, Aiello LP. Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes. 1999;48:1899-1906.
40. Tanaka Y, Katoh S, Hori S, et al. Vascular endothelial growth factor in diabetic retinopathy. Lancet. 1997;349:1520.
41. de Gooyer TE, Stevenson KA, Humphries P, et al. Rod photoreceptor loss in Rho_/_ mice reduces retinal hypoxia and hypoxiaregulated gene expression. Invest Ophthalmol Vis Sci. 2006;47: 5553-5560.
42. Gustavsson M, Wilson MA, Mallard C, et al. Global gene expression in the developing rat brain after hypoxic preconditioning: involvement of apoptotic mechanisms? Pediatr Res. 2007;61:444-450.
43. Mysliwiec M, Balcerska A, Zorena K, et al. The role of vascular endothelial growth factor, tumor necrosis factor alpha and interleukin-6 in pathogenesis of diabetic retinopathy. Diabetes Res Clin Pract. 2008;79:141-146.
44. Wang J, Xu X, Elliott MH, Zhu M, Le Y-Z. Müller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage. Diabetes. 2010;59:2297-2305.
45. Jasielska M, Semkova I, Shi X, et al. Differential role of tumor necrosis factor (TNF)-_ receptors in the development of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2010;51:3874-3883.
46. Vinores SA, Sen H, Campochiaro PA. An adenosine agonist and prostaglandin E1 cause breakdown of the blood-retinal barrier by opening tight junctions between vascular endothelial cells. Invest Ophthalmol Vis Sci. 1992;33:1870-1878.
47. Antonetti DA, Barber AJ, Khin S, et al. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes. 1998;47:1953-1959.
48. Antonetti DA, Barber AJ, Hollinger LA, et al. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1: a potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem. 1999;274:23463-23467.
49. Barber AJ, Antonetti DA. Mapping the blood vessels with paracellular permeability in the retinas of diabetic rats. Invest Ophthalmol Vis Sci. 2003;44:5410-5416.
50. Vinores SA, Van Niel E, Swerdloff JL, Campochiaro PA. Electron microscopic immunocytochemical evidence for the mechanism of blood-retinal barrier breakdown in galactosemic rats and its association with aldose reductase expression and inhibition. Exp Eye Res. 1993;57:723-735.
51. Vinores SA, Van Niel E, Swerdloff JL, Campochiaro PA. Electron microscopic immunocytochemical demonstration of blood-retinal barrier breakdown in human diabetics and its association with aldose reductase in retinal vascular endothelium and retinal pigment epithelium. Histochem J. 1993b;25:648-663.
52. Vinores SA, Derevjanik NL, Mahlow J, et al. Electron microscopic evidence for the mechanism of blood-retinal barrier breakdown indiabetic rabbits: comparison with magnetic resonance imaging. Pathol Res Pract. 1998;194:497-505.
53. Luna JD, Chan CC, Derevjanik NL, et al. Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1beta-mediated breakdown. J Neurosci Res. 1997;49:268-280.
54. Hofman P, Blaauwgeers HG, Tolentino MJ, et al. VEGF-A induced hyperpermeability of blood-retinal barrier endothelium in vivo is predominantly associated with pinocytotic vesicular transport and not with formation of fenestrations: vascular endothelial growth factor-A. Curr Eye Res. 2000;21:637-645.
55. Klaassen I, Hughes JM, Vogels IM, et al. Altered expression of genes related to blood-retina barrier disruption in streptozotocininduced diabetes. Exp Eye Res. 2009;89:4-15.
56. Behl Y, Krothapalli P, Desta T, et al. Diabetes-enhanced tumor necrosis factor-_ production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Amer J Pathol. 2008;172:1411-1418.
57. Behl Y, Krothapalli P, Desta T, et al. FOXO1 plays an important role in enhanced microvascular cell apoptosis and microvascular cell loss in type 1 and type 2 diabetic rats. Diabetes. 2009;58:917-925.
58. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10:45-65.
59. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science. 2002;296:1634-1635.
60. Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNFalpha therapy in rheumatoid arthritis. J Immunol. 1999;163:1521-1528.
61. Perry RT, Collins JS, Wiener H, et al. The role of TNF and its receptors in Alzheimer's disease. Neurobiol Aging. 2001;22:873-883.
62. Bradley JR. TN. F-mediated inflammatory disease. J Pathol. 2008; 214:149-160.
63. Sekut L, Connolly K. AntiTNF-alpha agents in the treatment of inflammation. Expert Opin Investig Drugs. 1998;7:1825-1839.
64. Tobinick E, Gross H, Weinberger A, Cohen H. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. Med Gen Med. 2006;8:25.
65. Tobinick E. Tumour necrosis factor modulation for treatment of Alzheimer's disease: rationale and current evidence. CNS Drugs. 2009;23:713-725.
66. Mohamed Q, Wong TY. Emerging drugs for diabetic retinopathy. Expert Opin Emerg Drugs. 2008;13:675-694.